Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268193 | 0.87 | L3MBTL1 (0.39) | TDP1L3MBTL1 | |
| SCHEMBL8131750 | 0.85 | F2 (0.34) | RARGF2ELANE | |
| SCHEMBL28367075 | 0.85 | TDP1 (0.33) | TDP1L3MBTL1 | |
| SCHEMBL8405940 | 0.82 | L3MBTL1 (0.34) | TDP1L3MBTL1 | |
| SCHEMBL5369031 | 0.81 | F2 (0.38) | RARGF2ELANETDP1L3MBTL1 | |
| SCHEMBL4757081 | 0.76 | L3MBTL1 (0.36) | TDP1L3MBTL1 | |
| SCHEMBL162033 | 0.75 | L3MBTL1 (0.40) | TDP1L3MBTL1 | |
| SCHEMBL3159666 | 0.74 | CTNNB1 (0.39) | F2ELANE | |
| SCHEMBL161774 | 0.74 | L3MBTL1 (0.46) | TDP1L3MBTL1 | |
| SCHEMBL4990062 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | RARG 3208/4885F2 4838/4885ELANE 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.